218 related articles for article (PubMed ID: 28617758)
1. Individualized Infliximab Treatment Guided by Patient-managed eHealth in Children and Adolescents with Inflammatory Bowel Disease.
Carlsen K; Houen G; Jakobsen C; Kallemose T; Paerregaard A; Riis LB; Munkholm P; Wewer V
Inflamm Bowel Dis; 2017 Sep; 23(9):1473-1482. PubMed ID: 28617758
[TBL] [Abstract][Full Text] [Related]
2. Self-managed eHealth Disease Monitoring in Children and Adolescents with Inflammatory Bowel Disease: A Randomized Controlled Trial.
Carlsen K; Jakobsen C; Houen G; Kallemose T; Paerregaard A; Riis LB; Munkholm P; Wewer V
Inflamm Bowel Dis; 2017 Mar; 23(3):357-365. PubMed ID: 28221247
[TBL] [Abstract][Full Text] [Related]
3. EHealth: self-management in inflammatory bowel disease and in irritable bowel syndrome using novel constant-care web applications. EHealth by constant-care in IBD and IBS.
Pedersen N
Dan Med J; 2015 Dec; 62(12):B5168. PubMed ID: 26621403
[TBL] [Abstract][Full Text] [Related]
4. Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study.
Roblin X; Boschetti G; Duru G; Williet N; Deltedesco E; Phelip JM; Peyrin-Biroulet L; Nancey S; Flourié B; Paul S
Inflamm Bowel Dis; 2017 Nov; 23(11):2048-2053. PubMed ID: 28945636
[TBL] [Abstract][Full Text] [Related]
5. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.
Hoekman DR; Brandse JF; de Meij TG; Hummel TZ; Löwenberg M; Benninga MA; D'Haens GR; Kindermann A
Scand J Gastroenterol; 2015; 50(9):1110-7. PubMed ID: 25865965
[TBL] [Abstract][Full Text] [Related]
6. Does infliximab short infusion have a beneficial impact on the quality of life in patients with inflammatory bowel diseases? A single centre prospective evaluation.
Principi M; Losurdo G; La Fortezza RF; Lopolito P; Lovero R; Grillo S; Bringiotti R; Ierardi E; Di Leo A
J Gastrointestin Liver Dis; 2015 Jun; 24(2):165-70. PubMed ID: 26114175
[TBL] [Abstract][Full Text] [Related]
7. A Mobile Infliximab Dosing Calculator for Therapy Optimization in Inflammatory Bowel Disease.
Piester T; Frymoyer A; Christofferson M; Yu H; Bass D; Park KT
Inflamm Bowel Dis; 2018 Jan; 24(2):227-234. PubMed ID: 29361094
[TBL] [Abstract][Full Text] [Related]
8. Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease.
Roblin X; Duru G; Williet N; Del Tedesco E; Cuilleron M; Jarlot C; Phelip JM; Boschetti G; Flourié B; Nancey S; Peyrin-Biroulet L; Paul S
Inflamm Bowel Dis; 2017 Jan; 23(1):126-132. PubMed ID: 28002129
[TBL] [Abstract][Full Text] [Related]
9. Safety of ferric carboxymaltose immediately after infliximab administration, in a single session, in inflammatory bowel disease patients with iron deficiency: a pilot study.
Cortes X; Borrás-Blasco J; Molés JR; Boscá M; Cortés E
PLoS One; 2015; 10(5):e0128156. PubMed ID: 26011514
[TBL] [Abstract][Full Text] [Related]
10. IgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease: impact on infliximab retreatment.
Fréling E; Peyrin-Biroulet L; Poreaux C; Morali A; Waton J; Schmutz JL; Guéant JL; Barbaud A
Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1200-8. PubMed ID: 26181108
[TBL] [Abstract][Full Text] [Related]
11. Serum infliximab concentrations in pediatric inflammatory bowel disease.
Hämäläinen A; Sipponen T; Kolho KL
Scand J Gastroenterol; 2013 Jan; 48(1):35-41. PubMed ID: 23148710
[TBL] [Abstract][Full Text] [Related]
12. eHealth: individualisation of infliximab treatment and disease course via a self-managed web-based solution in Crohn’s disease.
Pedersen N; Elkjaer M; Duricova D; Burisch J; Dobrzanski C; Andersen NN; Jess T; Bendtsen F; Langholz E; Leotta S; Knudsen T; Thorsgaard N; Munkholm P
Aliment Pharmacol Ther; 2012 Nov; 36(9):840-9. PubMed ID: 22971016
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients.
Dubinsky MC; Phan BL; Singh N; Rabizadeh S; Mould DR
AAPS J; 2017 Jan; 19(1):215-222. PubMed ID: 27739008
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice.
Buurman DJ; Maurer JM; Keizer RJ; Kosterink JG; Dijkstra G
Aliment Pharmacol Ther; 2015 Sep; 42(5):529-39. PubMed ID: 26113313
[TBL] [Abstract][Full Text] [Related]
15. Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation.
Berends SE; D'Haens GRAM; Schaap T; de Vries A; Rispens T; Bloem K; Mathôt RAA
Br J Clin Pharmacol; 2019 Jul; 85(7):1544-1551. PubMed ID: 30927375
[TBL] [Abstract][Full Text] [Related]
16. Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design.
Santacana E; Rodríguez-Alonso L; Padullés A; Guardiola J; Bas J; Rodríguez-Moranta F; Serra K; Morandeira F; Colom H; Padullés N
Ther Drug Monit; 2020 Feb; 42(1):102-110. PubMed ID: 31283556
[TBL] [Abstract][Full Text] [Related]
17. Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy.
Huang VW; Prosser C; Kroeker KI; Wang H; Shalapay C; Dhami N; Fedorak DK; Halloran B; Dieleman LA; Goodman KJ; Fedorak RN
Inflamm Bowel Dis; 2015 Jun; 21(6):1359-67. PubMed ID: 25989340
[TBL] [Abstract][Full Text] [Related]
18. New steps in infliximab therapeutic drug monitoring in patients with inflammatory bowel diseases.
Nemoz B; Ternant D; Bailly S; Gautier-Veyret E; Jourdil JF; Bonaz B; Stanke-Labesque F
Br J Clin Pharmacol; 2019 Apr; 85(4):722-728. PubMed ID: 30575085
[TBL] [Abstract][Full Text] [Related]
19. Nested case-control study on risk factors for opportunistic infections in patients with inflammatory bowel disease.
Gong SS; Fan YH; Han QQ; Lv B; Xu Y
World J Gastroenterol; 2019 May; 25(18):2240-2250. PubMed ID: 31143074
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with reduced infliximab exposure in the treatment of pediatric autoimmune disorders: a cross-sectional prospective convenience sampling study.
Funk RS; Shakhnovich V; Cho YK; Polireddy K; Jausurawong T; Gress K; Becker ML
Pediatr Rheumatol Online J; 2021 May; 19(1):62. PubMed ID: 33933127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
